Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response

Nature Medicine
A FriedmanI Tur-Kaspa

Abstract

Pyridostigmine, a carbamate acetylcholinesterase (AChE) inhibitor, is routinely employed in the treatment of the autoimmune disease myasthenia gravis. Pyridostigmine is also recommended by most Western armies for use as pretreatment under threat of chemical warfare, because of its protective effect against organophosphate poisoning. Because of this drug's quaternary ammonium group, which prevents its penetration through the blood-brain barrier, the symptoms associated with its routine use primarily reflect perturbations in peripheral nervous system functions. Unexpectedly, under a similar regimen, pyridostigmine administration during the Persian Gulf War resulted in a greater than threefold increase in the frequency of reported central nervous system symptoms. This increase was not due to enhanced absorption (or decreased elimination) of the drug, because the inhibition efficacy of serum butyryl-cholinesterase was not modified. Because previous animal studies have shown stress-induced disruption of the blood-brain barrier, an alternative possibility was that the stress situation associated with war allowed pyridostigmine penetration into the brain. Here we report that after mice were subjected to a forced swim protocol (shown p...Continue Reading

References

May 1, 1979·The Journal of Pharmacy and Pharmacology·P DirnhuberJ A Stratton
Feb 1, 1991·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·M GliksonM Revah
Jan 1, 1991·Annals of the New York Academy of Sciences·S I Harik, R N Kalaria
Sep 1, 1988·Acta Neurologica Scandinavica·Y IwasakiM Kinoshita
Apr 1, 1988·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·O UyamaM Sugita
Mar 1, 1981·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·D Y XiaS Q Pei
Apr 1, 1995·Current Opinion in Neurobiology·B S McEwen, R M Sapolsky
May 5, 1994·Nature·H Gavaghan
Jun 1, 1994·Toxicology and Applied Pharmacology·D W BlickS L Hartgraves
Jan 1, 1993·DNA and Cell Biology·T J EkströmP Taylor
Mar 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·R Ben Aziz-AloyaH Soreq
Jul 1, 1989·The European Journal of Neuroscience·A. Friedman, M. J. Gutnick

❮ Previous
Next ❯

Citations

Oct 9, 2001·Biotechnology and Bioengineering·T S MorH S Mason
Feb 17, 2001·Journal of Applied Toxicology : JAT·G D GriffithsD G Upshall
Sep 1, 2006·Archives of Toxicology·Praveena BaireddyCarey N Pope
Oct 1, 2008·Indian Journal of Clinical Biochemistry : IJCB·N GaurS Mishra
Feb 21, 2004·Journal of Neuroimmunology·Raymond J LangleyMohan L Sopori
Mar 6, 2003·Experimental Neurology·Lev PavlovskyAlon Friedman
Apr 29, 1998·Journal of the Neurological Sciences·Z AlamG B Steventon
Mar 29, 2001·Pharmacology, Biochemistry, and Behavior·F van HaarenB A Cody
Apr 2, 2003·Pharmacology, Biochemistry, and Behavior·Iveta BernatovaMariana Morris
Sep 11, 2003·Journal of Neuroimmunology·Susumu TanakaNobuyuki Amino
Feb 10, 2000·Toxicology·D A Lawrence, D Kim
Oct 6, 2000·Pediatric Neurology·P Parisi, A Francia
Oct 28, 1998·Journal of Physiology, Paris·R Drake-BaumannP S Spencer
Apr 1, 1999·Environmental Toxicology and Pharmacology·Y B KimY S Lee
Mar 1, 1997·Nature Medicine·I Azevedo, A Sarmento
Apr 1, 1997·Nature Medicine·R A Fishman
Dec 1, 1996·Nature Medicine·I Hanin
Jun 29, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Vipan K PariharAshok K Shetty
Feb 17, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard J Servatius, Kevin D Beck
Mar 5, 2002·Journal of Veterinary Pharmacology and Therapeutics·M RaekallioO Vainio
Sep 22, 1999·European Journal of Biochemistry·D GrisaruH Soreq
Mar 15, 2005·Journal of Toxicology and Environmental Health. Part a·David S BarberBernard S Jortner
Mar 22, 2001·Antisense & Nucleic Acid Drug Development·N GalyamH Soreq
Jun 9, 2001·Antioxidants & Redox Signaling·V E Thiel, K L Audus
Sep 6, 2008·Brain : a Journal of Neurology·María-Salud García-AyllónJavier Sáez-Valero
May 4, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Tama EvronTsafrir S Mor
Jan 28, 2009·Cephalalgia : an International Journal of Headache·A FerrariA Bertolini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.